Literature DB >> 1697358

Kinin receptor subtypes.

D Regoli1, N E Rhaleb, G Drapeau, S Dion.   

Abstract

Bradykinin, kallidin, and some of their metabolites exert potent biological effects in a variety of organs and tissues. These effects are mediated by specific receptors, of two different types B1 and B2, according to the classification proposed in 1980 by Regoli and Barabé. This classification has recently been challenged by several authors on the basis of data obtained with a variety of synthetic analogs (both agonists and antagonists) of bradykinin and kallidin. B2-receptor subtypes and even a new receptor type, B3 have been considered. Other workers have shown that some of the kinins' biological effects, such as the activation of prostaglandins or histamine release, may occur through nonreceptor mechanisms. Recently, a variety of new kinin-related peptides have been prepared and tested. In particular, new selective agonists for both B1 and B2 receptors have been identified and used for receptor characterization, particularly in complex biological systems. Antagonists are critically reviewed, because several of them are in effect partial agonists. Pure antagonists have been obtained and used for receptor characterization in various organs. Activation of receptors and nonreceptor mechanisms by kinins bring about direct effects on smooth muscles and other cells and indirect effects mediated by endothelium-derived relaxing factor, or by prostacyclin, prostaglandins, leukotrienes, histamine, etc. Interaction of kinins with their receptors activates second messengers that may be different from one cell to another (in the same tissue) and that are activated either by kinins or by other endogenous mediators released by kinins.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697358

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  20 in total

Review 1.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

2.  Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: A meta-analysis.

Authors:  Kazuaki Nishio; Shinji Kashiki; Hideaki Tachibana; Youichi Kobayashi
Journal:  World J Cardiol       Date:  2011-10-26

3.  Induction of kinin B1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery.

Authors:  D Pruneau; J M Luccarini; C Robert; P Bélichard
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

4.  Role played by NK2 receptor and cyclooxygenase activation in bradykinin B2 receptor mediated-airway effects in guinea pigs.

Authors:  T Sakamoto; H Tsukagoshi; P J Barnes; K F Chung
Journal:  Agents Actions       Date:  1993-07

5.  Bradykinin B2 receptor-mediated phosphoinositide hydrolysis in bovine cultured tracheal smooth muscle cells.

Authors:  K A Marsh; S J Hill
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

6.  Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.

Authors:  Julie Chao; Hang Yin; Lin Gao; Makoto Hagiwara; Bo Shen; Zhi-Rong Yang; Lee Chao
Journal:  Hypertension       Date:  2008-09-02       Impact factor: 10.190

7.  The kinin B1 receptor antagonist des-Arg9-[Leu8]bradykinin: an antagonist of the angiotensin AT1 receptor which also binds to the AT2 receptor.

Authors:  D Pruneau; A Duvoid; J M Luccarini; P Bélichard; J C Bonnafous
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

8.  Characteristics of the bradykinin-induced changes in intracellular calcium ion concentration of single bovine tracheal smooth muscle cells.

Authors:  K A Marsh; S J Hill
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway.

Authors:  Yu-Yu Yao; Hang Yin; Bo Shen; Robert S Smith; Yuying Liu; Lin Gao; Lee Chao; Julie Chao
Journal:  Cardiovasc Res       Date:  2008-08-09       Impact factor: 10.787

10.  The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis.

Authors:  Q-Z Li; J Zhou; R Yang; M Yan; Q Ye; K Liu; S Liu; X Shao; L Li; X-J Zhou; E K Wakeland; C Mohan
Journal:  Genes Immun       Date:  2009-03-05       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.